Content about Central retinal vein occlusion

September 24, 2012

The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.